Mosapride citrate dihydrate  (Synonyms: TAK-370 citrate dihydrate; AS-4370 citrate dihydrate)

Mosapride (TAK-370) citrate dehydrate is a gastroprokinetic agent with 5-hydroxytryptamine₄ receptor agonist activity and has been widely used in the research of a variety of gastrointestinal disorders. Mosapride citrate dihydrate potently inhibits Kv4.3 in a concentration-dependent manner with IC₅₀ values of 15.2 μM^[1]. Mosapride citrate dihydrateselectively stimulates upper GI motility in vivo^[2].

Mosapride (0.3-30 μM) exhibits an inhibitory activity against Kv4.3 with an IC₅₀ of 15.2 μM in a concentration-dependent manner. Mosapride also inhibits the open state of Kv4.3 currents during depolarization and accelerates the closed-state inactivation at subthreshold potentials^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Mosapride (Intravenous injection;0.3-3 mg/kg) dose-dependently increases the antral motor activity in conscious dogs which indicates that mosapride selectively stimulates upper gastrointestinal motility^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

650.05

C₂₇H₃₇ClFN₃O₁₂

636582-62-2

固体

White to off-white

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Sung KW, et al. Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells. Naunyn-Schmiedeberg's archives of pharmacology. 2013;386(10):905-16.  [Content Brief]

  [2]. Mine Y, et al. Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. The Journal of pharmacology and experimental therapeutics. 1997;283(3):1000-8.  [Content Brief]